PFE - Timing Favors Novavax's Delayed Approval Arrival Ahead of Peak COVID Vaccine Demand | Benzinga
Last week, Novavax Inc (NASDAQ: NVAX) received FDA authorization for its updated COVID-19 vaccine, targeting the omicron subvariant XBB.1.5 in individuals aged 12 and older.
Wall Street analysts are optimistic about Novavax's prospects despite its vaccine's release delay compared to Pfizer Inc (NYSE: PFE) and Moderna Inc's (NASDAQ: MRNA) offerings.
While Pfizer and Moderna struggled with supply and distribution issues, CNBC noted Novavax could benefit from improving logistics ...